The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Supramolecular PEGylation of biopharmaceuticals
Open accessAbstract
Significance: Pharmaceutical practice has transitioned away from small-molecule drugs to the use of biomolecules (peptides, proteins, and antibodies). Where formulation of small molecules focused primarily on solubility, biopharmaceuticals introduced an array of complications due to their more complex secondary and tertiary structures, contributing to concerns surrounding aggregation and denaturation over time in formulation. Here, we outline an approach using noncovalent supramolecular affinity to endow biopharmaceuticals with a polymer known to inhibit protein aggregation and improve solubility. This method stands in contrast to similar approaches to covalently graft the same polymer onto the protein, instead offering a broadly useful and modular formulation excipient that can be combined with authentic unmodified protein drugs to extend shelf life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Supersaxo, A., Hein, W. R., & Steffen, H. (1990) · Pharmaceutical Research · doi:10.1023/a:1015880819328 · Cited by 386
Subcutaneous drug delivery and the role of the lymphatics
McLennan, D. N., Porter, C. J. H., & Charman, S. A. (2005) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2005.05.006 · Cited by 259
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Cited by
Drug delivery by supramolecular design
Webber, M. J., & Langer, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00391a · Cited by 814
Self-citationOvercoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Supramolecular engineering of hydrogels for drug delivery
Bernhard, S., & Tibbitt, M. W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.002 · Cited by 363
Rasines Mazo, A., Allison-Logan, S., Karimi, F., Chan, N. J.-A., Qiu, W., Duan, W., O’Brien-Simpson, N. M., & Qiao, G. G. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00738e · Cited by 329
Cell membrane-derived vesicles for delivery of therapeutic agents
Le, Q.-V., Lee, J., Lee, H., Shim, G., & Oh, Y.-K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.020 · Cited by 181
Metadata
- Authors
- Webber, M. J., Appel, E. A., Vinciguerra, B., Cortinas, A. B., Thapa, L. S., Jhunjhunwala, S., Isaacs, L., Langer, R., & Anderson, D. G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-11-28
- Volume
- 113
- Issue
- 50
- Pages
- 14189-14194
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2559177805
- Cited by
- 201
- References
- 5
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Supramolecular PEGylation of biopharmaceuticals. https://app.cochat.ai/papers/10.1073/pnas.1616639113
- The paper
- Webber, M. J., Appel, E. A., Vinciguerra, B., Cortinas, A. B., Thapa, L. S., Jhunjhunwala, S., Isaacs, L., Langer, R., & Anderson, D. G. (2016). Supramolecular PEGylation of biopharmaceuticals. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1616639113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.